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Abstract: Autism and Autism Spectrum Disorders are a set of heterogeneous and enigmatic neurodevelopmental 
pathologies that arise from a variety of triggers.  In spite of outstanding scientific achievements in the study of the 
pathologies associated with autism and autism spectrum disorders, as of 2017 these developmental disorders are 
still without a curative treatment option.  This analysis reviews the therapeutic characteristics of stem cells and how 
they can provide clinical application and novel treatment options for autism spectrum disorders.  This review 
integrates a concise evaluation of all stem cell types utilized in autism research and treatment and associates the 
efficacy, safety, and tolerability findings of the most current stem cell-autism spectrum disorder treatments.  
Concluding data outlines budgetary and funding rates associated with stem cell-autism spectrum disorder research 
(2012-2017) and concludes with avenues for novel research and treatment options.    
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Introduction 
 Autism and Autism Spectrum Disorders (ASDs) are a set of heterogeneous and enigmatic 
neurodevelopmental pathologies that arise from genetic susceptibility, environmental triggers, 
and epigenetic processes activated by those environmental triggers. As defined by the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published by the American 
Psychiatric Association, Autism Spectrum Disorder is categorized in rank of severity (Table 1) 
and characterized by persistent deficits in both social-emotional reciprocity and verbal and 
nonverbal communicative behaviors.  Additional social and behavioral symptoms of ASDs 
include stereotyped or repetitive motor movements and insistence on sameness.  
 In review of the physiologic underpinnings of ASDs, it is found that several biochemical 
and cellular events are associated with ASDs: oxidative stress, endoplasmic reticulum stress, 
decreased methylation capacity, limited production of glutathione, mitochondrial dysfunction, 
intestinal dysbiosis and inflammation, increased toxic metal burden, impaired detoxification, 
and dysregulation of the brain’s intrinsic immune system - including autoimmunity and 
activation of neuroglial cells (Bradstreet, Smith, et al, 2010;  Ming, Brimacombe, et al, 2008).  
Despite this extensive body of evidence for an underlying immunotoxicological event in the 
development of autism, the exact origins of pathogenesis and pathophysiology of ASDs remain 
to be fully elucidated (Siniscalco, Bradstreet, et al, 2013). 
 The prevalence of ASDs is rapidly increasing. The DSM-5 report frequencies for ASDs 
approaching 1% of the population while the Centers for Disease Control and Prevention (CDC) 
report that 1 in 68 children are diagnosed with ASDs (reported in 2012 with a birth year of 
2004). This is a change that cannot be explained by mere data-gathering methods, nor is it likely 
due to changed diagnostic approaches (Baio, 2012). 
 In spite of outstanding achievements in the study of pathogenesis of autism and other 
ASDs, including immunological and immunegenetic research resulting in the new trends of 
specific therapy, autism remains one of the unresolved issues of modern neurology (Bradstreet, 
Sych, et al, 2014).     
 
 
 
 
Literature elucidates the current facets of ASD treatment and divides them into 
behavioral, nutritional, and biomedical approaches, with no defined ‘gold-standard’ existing.  
ASD pharmacologic therapies only target specific limited behavioral symptoms (Figure 1) and 
fail to resolve the basic underlying biological etiologies.  Current research suggests that stem cell 
(SC) therapies represent the future of molecular and regenerative medicine for what would 
otherwise be untreatable human diseases.  Stem cells are also suitable for developing cell-based 
patient-specific pharmacotherapies (Siniscalco, Giordano, et al, 2012; Siniscalco, Pandolfi, et al, 
2012).  These characteristics suggest that stem cells can provide therapeutic applications and new 
treatment options for ASDs. 
Past studies and reviews have independently delineated various stem cell types used in 
the treatment of ASDs.  There have also been independent studies which demarcate Stem Cell-
Autism Spectrum Disorder (SC-ASD) treatment protocols and ongoing SC-ASD treatment 
options however, no review has ever encompassed all of these topics while also including 
examples of treatment centers that offer the most current SC-ASD treatment options. 
This analysis proves to be a novel approach in that it will incorporate multiple data points 
into one study.  This review integrates a concise evaluation of all SC types utilized in ASD 
research and treatments (as of 2017) and associates the efficacy, safety, and tolerability findings 
of the most current SC-ASD treatments. Also included in this analysis are the budgetary and 
funding rates associated with SC-ASD research (2012-2017) and avenues for new SC-ASD 
research and treatment.  The review concludes with delineated options of treatment centers that 
offer the most advanced SC-ASD therapies.   
 
 
 
 
 
 
 
 
Table 1:  
Severity Levels for Autism Spectrum Disorder 
  
Severity level Social communication Restricted, repetitive behaviors 
Level 3 
"Requiring very substantial 
support” 
Severe deficits in verbal and 
nonverbal social communication 
skills cause severe impairments in 
functioning, very limited initiation 
of social interactions, and minimal 
response to social overtures from 
others. For example, a person with 
few words of intelligible speech 
who rarely initiates interaction and, 
when he or she does, makes unusual 
approaches to meet needs only and 
responds to only very direct social 
approaches 
 
Inflexibility of behavior, extreme 
difficulty coping with change, or 
other restricted/repetitive behaviors 
markedly interfere with functioning 
in all spheres. Great 
distress/difficulty changing focus or 
action. 
Level 2 
"Requiring substantial support” 
Marked deficits in verbal and 
nonverbal social communication 
skills; social impairments apparent 
even with supports in place; limited 
initiation of social interactions; and 
reduced or abnormal responses to 
social overtures from others. For 
example, a person who speaks 
simple sentences, whose interaction 
is limited to narrow special 
interests, and how has markedly odd 
nonverbal communication. 
 
Inflexibility of behavior, difficulty 
coping with change, or other 
restricted/repetitive behaviors appear 
frequently enough to be obvious to 
the casual observer and interfere with 
functioning in a variety of contexts. 
Distress and/or difficulty changing 
focus or action. 
Level 1 
"Requiring support” 
Without supports in place, deficits in 
social communication cause 
noticeable impairments. Difficulty 
initiating social interactions, and 
clear examples of atypical or 
unsuccessful response to social 
overtures of others. May appear to 
have decreased interest in social 
interactions. For example, a person 
who is able to speak in full 
sentences and engages in 
communication but whose to- and-
fro conversation with others fails, 
and whose attempts to make friends 
are odd and typically unsuccessful. 
Inflexibility of behavior causes 
significant interference with 
functioning in one or more contexts. 
Difficulty switching between 
activities. Problems of organization 
and planning hamper independence. 
*data obtained from DSM-5 
 
 
 
  
Figure 1. Categories of Medications Used by Children with ASD.  Most of these medications have not been 
approved by the United States Food and Drug Administration (FDA) to treat ASD in adults or children however, 
there is evidence in research literature that supports their use in ASD. Stimulants treat: distractibility, attention 
deficits, and hyperactivity.  Neuroleptics (i.e.: antipsychotics) treat: irritability, tantrums, aggression, and unstable 
mood.  Antidepressants treat: stereotypic (repetitive) behaviors, unstable mood, anxiety, and depression.  
Anticonvulsants treat: unstable mood, seizures (epilepsy), and migraine headache.  Anxiolytics treat: anxiety. 
Antifungals (e.g.: Diflucan) are used to treat the overgrowth of yeast-like fungus. Some clinicians believe that 
symptoms of ASD are exacerbated by the overgrowth of these fungi. Other medications in the study included 
antibiotics, antihistamines, and laxatives. These data include an N of 3,140 medications.  These values are based on 
Interactive Autism Network (IAN) data collected on March 20, 2008. 
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 Methods 
The aim of this review was to define the progress in using stem cells in the treatment of 
autism spectrum disorders.  In order to ensure a precise analysis, multiple research methods were 
implemented in order to: define the types of stem cells used in treating ASDs, establish efficacy 
in the treatments, and identifying appropriate treatment facilities.   
First, a comprehensive evaluation of peer-reviewed journals was conducted.  Key terms 
utilized during this search included: stem cells, autism, autism spectrum disorders, cell biology, 
pediatrics, cell, brain.  Secondly, a comprehensive appraisal of peer-reviewed journal articles 
was conducted.  Key words associated with this search included: treatment, stem cell treatment, 
autism, autism spectrum disorder.   One U.S. Governmental database was used during these 
journal article and journal searches: ncbi.nlm.nih.gov (PubMed). In addition to the compilation 
of a journal articles, the reference section for each article chosen was reviewed in order to locate 
supplementary useful articles.   
Current diagnostic medical manuals were utilized to ensure appropriate diagnostic criteria 
and statistics. 
In order to ensure current research and funding data were obtained, multiple 
governmental, academic, and research institutional websites were utilized: www.cdc.gov, 
clinicaltrials.gov, autismcenter.duke.gov., cellmedicine.com, stemcelltreatmentnow.com.   
Five International treatment centers were reviewed via emails, phone calls, and web 
searches.  Final data collection methods included interviews with patients and families associated 
with SC-ASD treatments.  
All defined research methods were conducted in such a manner to ensure data was 
reflective of 2017 outcomes.   
 
   
 
 
 
 
 Results  
Although autism and ASDs are characterized by a variety of deficits in both social-
emotional reciprocity and verbal and nonverbal communicative behaviors, there are two common 
consistent pathologies associated with children diagnosed with ASDs.  The first of these 
pathologies is neural hypoperfusion. Multiple areas of the brain are affected in ASDs (Figure 2) 
and when these regions experience diminished oxygenation the resultant effect is cerebral 
ischemia.  The second common pathology associated with ASD is immune dysregulation. This 
pathology can present as; a chronic immunologically medicated inflammatory condition in the 
gut, an upregulation of inflammatory cytokines in the ASD brain, and as alterations in immune 
cells such as T cells, B cells, monocytes, natural killer cells, and dendritic cells. (Riodan, 2016; 
Noriega, Savelkoul, 2014; Bjorklund, Saad, et al, 2016).  These neural and immune 
dysregulations provide specific targets for specific stem cell therapies.   
Stem cells possess several useful characteristics which suggests their potential therapeutic 
application for ASDs.  Siniscalco and colleagues (2013) report that these characteristics are (1) 
their self-renewal ability: stem cells are able to generate more identical stem cells; (2) 
differentiation process: through it, the cells give rise to more differentiated cells; and (3) 
paracrine regulatory functions: stem cells synthesize and release a complex and implantable 
“biopharmacy”, capable of regulating cell differentiation, tissue and organ repair, and anti-
inflammatory actions in the recipient. These paracrine functions of stem cells (i.e.: the 
biopharmacy or the secretome) are attracting much attention (Razavi, Razavi, et al, 2013; Drago, 
Cossetti, et al, 2013).  It has already been proposed that in ASD cell-based treatment, the positive 
effects that could be medicated by stem cells could be achieved through the trophic and 
immunomodulatory properties (Siniscalco, Sapone, et al, 2012). Additional research suggests 
that implanted stem cells (whether autologous or donor) are able to affect the recipient immune 
system through two proposed mechanisms: (1) cell-to-cell contact activation mechanism, 
through which transplanted stem cells switch proinflammatory macrophages to anti-
inflammatory macrophages (Zheng, Ge, et al, 2013; Siniscalco, Giordano, et al, 2011), and (2) 
the paracrine-secretome activity (Zemel'ko, Kozhukharova, et al, 2013).  Siniscalco, and 
colleagues (2013) propose that through these mechanisms, stem cells could simultaneously 
counterbalance the immune system aberrations while activating endogenous restorative 
mechanisms within damaged tissues contributing to recovery of functional deficits.  It has also 
 been hypothesized that cell replacement, by transplanted stem cells, might not be a necessary 
prerequisite for effective stem cell therapies due to the aforementioned mechanisms proving to 
be sufficiently restorative however, these restorative functions are dependent upon the stem cell 
type and the programming of the stem cell.  
 
 
 
Figure 2. Areas of the Brain Affected by Autism (1) Amygdala: responsible processing emotions and behavior 
(including aggression); (2) Hippocampus: involved in learning and memory; (3) Brain Stem: serves as a relay link 
passing messages between the body and the cerebral cortex. Also controls the primitive functions of the body which 
ae essential to survival (breathing, heart rate); (4) Cerebellum: concerned with coordination and control of voluntary 
muscular activity; (5) Corpus Callosum: white-matter bridge between the two hemispheres of the brain – allowing 
the two hemispheres to communicate with one another; (6) Basal Ganglia:  masses of gray-matter-lining in the 
brains cerebral cortex and involved in the control of automatic body movement; (7) Cerebral Cortex: thin layer of 
gray matter, two-thirds of this area is deep in the tissues and folds of the cerebrum.  This is the center for higher 
mental functions, perception, behavioral responses, and other functions.  
 
 As of 2017 a variety of stem cell types have been considered and/or utilized in such stem 
cell therapies, which have resulted in varied outcomes. 
Human Embryonic Stem Cells  
Human Embryonic Stem Cells (hESCs) are derived from the inner cell mass (ICM) of the 
blastocyst (early-stage preimplantation embryo).  These hESCs are known to be pluripotent 
which gives them the capability of differentiating into any of the three germ layers (i.e.: 
ectoderm, mesoderm, and endoderm). However, the utilization of hESCs in the clinical setting 
are plagued with numerous disadvantages, one of which is that of histocompatibility (i.e.: graft-
versus-host-disease). Tang, Weissman, and colleagues (2013) go on to confirm that in the 
absence of a life-long regimen of antirejection medications, the cells would be expected to be 
rejected by the recipient immune system once HLA-II expression occurred. Furthermore, the 
implantation of hESCs into a recipient have been known to produce tumor-like formations 
(teratoma) which contain tissues from all three germ layers.  The hESCs ability to form teratoma 
is a sine qua non characteristic of pluripotent stem cells (Prokhorova, Harkness, et al, 2009).  
Siniscalco and colleagues (2013) confirm that the proper regulation of post-transplantation of 
hESCs is the formidable challenge and that hESCs are known to derive their differentiation 
characteristics from the recipient environment. These challenges of chimeric engraftment are far 
from understood in the pediatric population, and thus the potential outcome from hESCs is 
poorly characterized in the scientific literature and is a source of concern (Siniscalco, et al, 2013) 
As this data relates to ASDs, it has been demonstrated that an altered immune cell ratio is 
sometimes associated with a decreased number of T lymphocytes (Siniscalco, Sapone, et al, 
2012).  The ability of ESCs to differentiate into hematopoietic cell lineages, giving rise to all 
blood cell types and subtypes of the immune system (i.e.: T cells, NK cells, and dendritic cells), 
could be used in immune-altered pathologies, such as ASDs, which require induction of the 
immune response in an antigen-specific manner (Ng, Davis, et al, 2005; Nakamura, Hiroyama, et 
al, 2011; Senju, Hirata, et al, 2010). However, the complications encountered with the use of 
hESCs as a treatment modality outweigh the benefits and the long-term therapeutic benefits have 
proven to be suboptimal. As of the publication of this review, eight clinical trials were ongoing 
in the study of treating ASDs with the use of human stem cells however, none of these trials 
included the use of hESCs.   
Based on these data, it is uncertain whether hESCs are ready for clinical use. 
 Fetal Stem Cells 
Fetal Stem Cells (FSCs) can be isolated from fetal blood and bone marrow as well as 
from other fetal tissues (amniotic fluid, placenta, chorion, or umbilical cord). Those derived from 
fetal tissues are often referred to as extraembryonic FSCs due to their originating in the 
extraembryonic membranes.  These FSCs are acquired after birth and are considered pluripotent. 
This pluripotency gives them the ability to differentiate into the three germ layers subtypes: 
ectoderm (including the brain), mesoderm, and endoderm.  FSCs have great potential for clinical 
use; as they possess immune-regulatory functions found in mesenchymal stem cells yet they 
exhibit a greater expansion capacity and enhanced plasticity (Klemmt, Vafaizadeh, et al, 2011). 
Early gestational fetal neuronal tissue is of particular interest to neurodegenerative disease 
therapies and may serve as a model for ASD interventions.  In part, this is because early FSCs 
have minimal or no expression of MHC-I and no MHC-II (Laguna Goya, Busch, et al, 2011). It 
has also been found that FSCs express HLA-G which belongs to the HLA class I heavy 
paralogues. HLA-G is involved in the presentation of foreign antigens to the immune system 
thereby providing a factor of tolerance. And, it is this added benefit that convenes increased 
viability post-transplantation.   
Benefits that are seen in fetal mesenchymal stem cells that are not seen in ECSs are that 
they do not form teratoma post-transplantation and they are obtained from tissues that would 
otherwise be discarded as medical-waste.   FSCs hold a multitude of additional benefits: they are 
known to exert strong immunomodulatory effects, they possess a stable phenotype, they 
demonstrate less senescence, they are able to release several diffusible neurotrophic and growth 
factors, and they have the capacity to suppress proinflammatory cytokines. An additional benefit 
of FSCs could be due to paracrine trophic actions on host tissues affected by ASDs, rather than 
cell replacement.  Siniscalso and colleagues (2013) report that as FSCs are derived from all germ 
layers, they retain their tissue-specific instructions and are therefore regulated properly, unlike 
pluripotent ESCs. In this way, cell or tissue/organ FSCs could restore dysfunctional development 
of the brain, gut, and immune system.   
The positive qualities and mechanism of action of FSCs may contribute to the success of 
allogeneic FSC transplants in ASD therapies. 
 
 
 Neural Stem Cells  
 Neural stem cells (NSCs) exist not only in the embryo, but also in the adult brain 
neurogenic region: the subventricular zone (SVZ) of the lateral ventricle. ESCs acquire NSC 
identity with a default mechanism. Under the regulations of leukemia inhibitory factor (LIF) and 
fibroblast growth factors, the NSCs then become neural progenitor cells (NPCs) – (Hsu, Lee, et 
al, 2007).  It has been shown that these multipotent cells show self-renewing capacities and are 
able to generate multiple cell types of the mammalian central nervous system.  The capacity of 
integration into neural tissue, replacing damaged cells and reconstructing neural circuitry are the 
main characteristics of NSCs with potential usefulness for treating ASDs.  Research also shows 
that in autism, excitatory and inhibitory cortical neurons contribute to minicolumn structure 
abnormalities and functional imbalances in the cortex. It has been hypothesized that transplanted 
NPCs could promote neurogenesis through their contributing to the changes in the brain 
microenvironment.  However, before being suitable for clinical applications in 
neurodegenerative diseases or ASDs, some critical issues with the use of NPCs require further 
investigation.  A reliable source of sufficient autologous NPCs needs to be identified. Further, 
the regulation of postimplantation neural plasticity and differentiation of NSCs in the child or 
adult nervous system must be further defined (Hsu, Lee, et al, 2007).   
Mesenchymal Stem Cells  
 Mesenchymal stem cells (MSCs) are defined as multipotent stromal cells of mesodermal 
origin which possess a self-renewing capacity.  MSCs can be easily obtained and from multiple 
sources. These cells are found primarily in the bone marrow and adipose of children and adults 
but can also be derived from both the umbilical cord (UC), umbilical cord blood (UCB), and 
placenta. The cells acquired from bone marrow stroma and are typically obtained from donors 
via a bone aspirate surgical procedure through the iliac-crest, tibia, femur, or vertebrae while 
adipose cells are easily harvested, generally from the abdominal region, through a minimally-
invasive small volume lipo-aspirate procedure. UC-MSCs and UCB-MSCs are both available in 
relatively large quantities from morally acceptable sources with collection consisting of no 
painful or invasive techniques. 
Regardless of collection site, MSCs can differentiate into a multitude of cell types 
including osteoblasts, chondrocytes, myocytes, adipocytes, hepatocytes, cardiomyocytes, and 
neurons.  This capacity of a cell to differentiate into mesenchymal lineages in vitro is one of the 
 essential requisites of the International Society of Cellular Therapy (ISCT) for a cell to be 
defined as an MSC.  In regards to the overall research benefits of MSCs, the ISCT also reports 
that MSCs possess the capacity to grow in adherence to the plastic surface of dishes when 
maintained in standard culture conditions. When these standard culture conditions are 
maintained, MSCs can be readily stores and will quickly expand.  The ISCT goes on to report 
additional minimal criteria for cells to be defined as MSCs: They must express cytospecific cell 
surface markers (CD105, CD90, and CD73) and must lack expression for all other surface 
markers (CD45, CD34, CD14 or CD11b, CD79alpha or CD19, and HLA-DR).   
Research has shown numerous benefits of MSCs, some of which include their immune-
modulating capabilities and their absence of uncontrollable growth and tumor formation.  These 
qualities attest to their clinical safety and to their usefulness for transplantation purposes and, 
upon transplantation, MSCs are able to readily migrate to the site of injury in order to assist in 
the restorative process.  MSCs also possess strong anti-inflammatory and immunosuppressive 
activity, rendering them very attractive for successful autologous, as well as heterogeneous, 
transplantations without requiring pharmacological immunosuppression (Le Blanc & Pittenger, 
2005; Petrie Aronin & Tuan, 2010). Additionally, since MSCs are able to express in vivo 
immunosuppressive factors, the need of genetic modification or pretreatment before 
transplantation are negated therefore, there is no further concern of immune rejection problems.  
It is this MSC-mediated immune system modulating activity that could prove to be a key 
mechanism in ASD therapy.    
As previously discussed, immune-dysregulation is known to be one of the consistent 
findings with ASD diagnosis.   ASD children show imbalances in CD3+, CD4+, and CD8+ T 
cells, as well as natural killer (NK) cells.  In addition, peripheral blood mononuclear cells 
(PBMCs) extracted from ASD children show over production of caspase proteases, 
proinflammatory cytokines, and cannabinoid-type-2 receptors resulting in long-term immune 
alterations and proinflammatory cellular events (Siniscalco, Sapone, et al, 2012; Enstrom, Onore, 
et al, 2010; Siniscalco, Sapone, et al, 2013). A notable research consideration is that MSC 
immunoregulatory effects could restore the immune-dysregulation in ASD (Figure 3). 
       
 
Figure 3. Paracrine and immunomodulatory effects as possible mechanisms of action of mesenchymal stem cells 
(MSCs) in autism spectrum disorder (ASD) treatment. In humans, ASDs are associated with immune alterations and 
pro-inflammatory cytokines (i.e., IL-1β) over-production. These cytokines are able to trigger pro-inflammatory 
cellular events. Data from in vitro models show that MSCs are able to affect not only T cells, but also other cells of 
the immune system (i.e., NK cells). Immunoregulatory properties of MSCs are through secretion of large amounts of 
several bioactive molecules (paracrine activity), that is, PGE-2, IL-10. These molecules cause the inhibition or the 
unresponsiveness of T-cell mediated responses. (Siniscalco, Sapone, et al. 2012). 
 
MSCs could also have restorative effects on the neural-dysregulation of ASD.  
Supporting this potential application of cell therapies for ASDs, transplanted MSCs are able to 
promote synaptic plasticity and functional recovery (Rodrigues Hell, Silva Costa, et al, 2009; 
Chang, Chen, et al, 2011). Additionally, the mobilization of MSCs to the site of neural injury 
could provide potential ameliorative effects in ASD treatment (Table 2).  This mobilization is a 
key facet in the proposed mechanism of action that MSCs have in regards to neural restoration 
and tissue repair. 
 
  
Table 2 
Potential ameliorative effects mediated by MSCs in ASD treatment 
 
ASD-induced changes in human brain 
 
Potential MSC ameliorative roles seen in preclinical 
models 
 
Abnormal functioning 
 
 
Improving functional recovery 
Cerebellum alterations 
 
Integrating in altered brain and restoring damaged 
functions 
Decreased number of Purkinje cells (PCs) 
 
Restoring cerebellar PCs 
Defective cortical organization 
 
Reinforcing cortical plasticity 
Note. source: (Siniscalco, Sapone, et al. 2012). 
 
 MSCs have been proven to aid in the restorative factors associated with immune and 
neural dysregulation of ASDs, but there is now a burgeoning science dedicated to the role of 
epigenetic factors associated with ASDs and how MSCs can contribute to the amelioration of 
these factors.  As we delineate, epigenetics is a mechanism that controls gene expression without 
changing DNA sequence but by changing chromosomal histone modifications and its 
abnormality is associated with several neurodevelopmental diseases. Since epigenetic 
modifications are known to be affected by environmental factors such as nutrition, drugs and 
mental stress, autistic diseases are not only caused by congenital genetic defects, but may also be 
caused by environmental factors via epigenetic mechanism (Miyake, Hirasawa, et al, 2012). 
Siniscalco and colleagues (2013) report that native MSCs in ASD could not inhibit the epigenetic 
processes triggered by the environmental factors which ultimately led to the development of the 
autistic phenotype.   
Further research needs to be done in order to determine whether or not all autologous MSCs 
are capable of responding appropriately to induce the healing effects needed for neuro-
rehabilitation.   
Through this continued evaluation of each source of MSC we are reminded that MSCs 
can also be isolated from adipose tissue. Adipose tissue is derived from the mesoderm during 
embryonic development and is present in every mammalian species, located throughout the 
body. Adipose tissue serves as an endocrine organ, functioning to maintain energy metabolism  
  
through the storage of lipids. While two types of adipose tissue exist (brown and white), white 
adipose yields the commonly studied adipose-derived mesenchymal stem cells (AD-MSCs) – 
(Minteer, Marra, et al, 2013).  Research indicates that the clinical benefits of AD-MSCs are they 
exhibit anti-inflammatory characteristics, and have the ability to differentiate into other tissue 
types of the mesoderm-including adipogenic, osteogenic, chondrogenic, myocyte, and other 
mesenchymal lineage.  Although clinical trials have been conducted using AD-MSCs in ASDs 
(Table 3) there is still much research to perform in order to determine their full clinical potential.  
Some such points to investigate are their differentiation processes into cell lineages apart from 
adipocytes post-reimplantation, Additionally, Siniscalco and colleagues (2013) report that there 
is no evidence that the re-administration of MSCs extracted from adipose tissue will overcome 
the intrinsic sense of the MSCs to return to the surgical harvest (lipo-aspirate) site to initiate 
repair.  It is also likely that cell preparations from the lipo-aspirate might contain a 
heterogeneous population of cells which equates to concerns of cell purity and molecular 
phenotype.   
 Continued research on AD-MSC biology is needed before their use in ASD therapy can 
be further understood. 
 
 
 
Table 3 
Current Stem Cell Clinical Trials Associate with the Treatment of ASDs  
Study Condition Intervention Status Link 
Autologous Bone Marrow 
Stem Cells for Children with 
Autism Spectrum Disorders 
 
Autism; 
Autism 
Spectrum 
Other:  Stem Cells Recruiting https://clinicaltrials.gov/ct2/s
how/NCT01740869?term=st
em+cells+autism&rank=1 
 
Autologous Bone Marrow 
Stem Cell Therapy for 
Autism 
 
Autistic 
Disorder 
Biological: Autologous 
Bone Marrow 
Mononuclear Cells 
Completed https://clinicaltrials.gov/ct2/s
how/NCT02627131?term=st
em+cells+autism&rank=3 
 
A Clinical Trial to Study the 
Safety and Efficacy of Bone 
Marrow Derived Autologous 
Cells for the Treatment of 
Autism 
 
Autism Biological: STEM 
CELL THERAPY 
Unknownϯ https://clinicaltrials.gov/ct2/s
how/NCT01836562?term=st
em+cells+autism&rank=6 
 
Stem Cell Therapy in Autism 
Spectrum Disorders 
 
 
Autism 
Spectrum 
Disorders 
Procedure: Autologous 
bone marrow 
mononuclear cell 
transplantation 
Completed https://clinicaltrials.gov/ct2/s
how/NCT01974973?term=st
em+cells+autism&rank=7 
 
 
Allogeneic Umbilical Cord 
Mesenchymal Stem Cell 
Therapy for Autism 
 
Autism Biological: Umbilical 
cord mesenchymal stem 
cells 
Active, not 
recruiting 
https://clinicaltrials.gov/ct2/s
how/NCT02192749?term=st
em+cells+autism&rank=2 
 
Safety and Efficacy of Stem 
Cell Therapy in Patients with 
Autism 
Autism Biological: human cord 
blood mononuclear 
cells; 
Biological: human cord 
blood mononuclear 
cells and human 
umbilical cord 
mesenchymal stem 
cells 
 
Completed https://clinicaltrials.gov/ct2/s
how/NCT01343511?term=st
em+cells+autism&rank=4 
 
 
Autologous Cord Blood Stem 
Cells for Autism 
 
 
Autism Biological: Autologous 
cord blood Stem Cells; 
Biological: Placebo 
Active, not 
recruiting 
https://clinicaltrials.gov/ct2/s
how/NCT01638819?term=st
em+cells+autism&rank=5 
 
Adipose Derived Stem Cell 
Therapy for Autism 
 
Autism Procedure: Fat 
Harvesting and Stem 
Cell Injection 
Unknownϯ https://clinicaltrials.gov/ct2/s
how/NCT01502488?term=st
em+cells+autism&rank=8 
Note. ϯ = Study has passed its completion date and status has not been verified in more than two years. 
 Bone marrow-derived mesenchymal stem cells (BM-MSCs) are the prototypical MSC 
and are the most well studied of all stem cells.  In 1999 Mark Pittenger and his colleagues first 
reported the multi-lineage potential of adult human mesenchymal stem cells.  However, it is also 
reported that advanced donor age diminishes the proliferative capacity as well as having effects 
on the cells anti-inflammatory capacity and homing ability (Stenderup, Justesen, et al, 2003; 
Bustos, Huleihel, et al, 2014). This diminished cellular “fitness” marks BM-MSCs as a 
suboptimal choice when aiming to treat childhood disorders such as ASDs.   
 While BM-MSCs have been known to be the prototypical MSC for clinical purposes, 
there is emerging evidence that umbilical cord-derived and umbilical cord blood-derived 
mesenchymal stem cells (UC-MSCs and UCB-MSCs) might set a new ‘platinum standard’ of 
care.  UC and UCB may also prove to be a richer source of MSCs, based on colony forming unit-
Fibroblastic efficiency, and generate MSCs with greater immunomodulatory potential than BM-
MSCs (Wegmeyer, Bröske, et al, 2013).  Research continues to demonstrate that ASD, and its 
degrees of severity, have been significantly correlated with inflammatory and neuro-
inflammatory cytokines including macrophage-derived chemokine (MDC) and thymus and 
activation-regulation chemokine (TARC) and based on these findings, it is hypothesized that 
umbilical cord-blood derived cell therapies may have the potential in alleviating ASD symptoms 
by modulating inflammatory processes in the brain (Riordan, 2016; Dawson, Sun, et al, 2017). 
 As the review of stem cells continues, data confirms that the continued advancement of 
stem cell research, as it pertains to treatments for ASDs, is more important now than it has ever 
been.  According to the CDC, there has been a substantial increase in the reported cases of ASDs 
over the past several decades.  Reports indicate that in 1996, 3.4:1000 children were diagnosed 
with ASDs as compared to their latest study (2012) indicating that 14.6:1000 children were 
diagnosed with ASDs. This is over a four-fold increase in only a 16 year time span.  With this 
dramatic increase we are still struggling to understand the pathophysiologies associated with 
ASDs, the defined mechanisms of these pathophysiologies and most importantly: how we can 
render a curative therapy. Tremendous amounts of research has been conducted on the 
behavioral, nutritional, and pharmacologic treatments of ASDs however, there is still no 
optimized standard of care.  Current research suggests that stem cell therapies represent the 
future of molecular and regenerative medicine for what would otherwise be untreatable human 
 diseases.  Stem cells are also suitable for developing cell-based patient-specific 
pharmacotherapies (Siniscalco, Giordano, et al, 2012; Siniscalco, Pandolfi, et al, 2012).  These 
characteristics suggest that stem cells can provide therapeutic applications and new treatment 
options for ASD patients. In order to develop these therapeutic applications, treatment modalities 
have had to endure years of stringent research and clinical trials before their clinical application 
is permissible.  
Funding for such research is provided by a number of entities.   The United States (U.S.) 
Governmental funding entity is that of the National Institutes of Health (NIH) which invests 
nearly $32.3 billion1 annually in medical research for the American people.  More than 80% of 
the NIH's funding is awarded through nearly 50,000 competitive grants to more than 300,000 
researchers at more than 2,500 universities, medical schools, and other research institutions in 
every state and around the world (NIH, 2017). This budget is allocated to 265 research, 
condition, and disease categories - including human stem cell research and human stem cell 
research as it pertains to the treatment of ASDs.  The NIH confirms that during the years of 2012 
through 2017, an average of $916 million was granted to the area of general human-SC research 
(Table 4), and $11.5 million of those funds were then allocated to the subspecialty of studying 
the treatment of ASDs with the use of human stem cells (Table 5).  These monies were allocated 
through 34 grants which were awarded to nine various research institutions (Table 6).  There are 
two important caveats that should be taken into account when reading these data: These values 
do not include privately funded research projects nor do they include European trials/research. 
 
 
 
 
 
                                                          
1 This amount reflects the sum of discretionary budget authority of $31,381 million received by NIH in FY 2016 
under The Consolidated Appropriations Act of 2016, Public Law (P.L.) 114-113, $780 million derived from PHS 
Evaluation financing, and mandatory budget authority of $150 million for special type 1 diabetes research 
authorized per P.L. 113-93 and P.L. 114-10 (NIH, 2017). 
 Table 4 
National Institutes of Health Universal Funding Rates for Human Stem Cell Research  
  
Fiscal Year 
 
 
SC Type 
Researched 
(dollars in 
millions & 
rounded) 
 
2012 
(actual) 
 
2013 
(actual) 
 
2014 
(actual) 
 
2015 
(actual) 
 
2016 
 
 
2017 
      
Estimated costs 
 
 
hESC 
 
$146 
 
$146 
 
$166 
 
$180 
 
$190 
 
$190 
 
hiPSC 
 
$175 
 
$199 
 
$280 
 
$282 
 
$296 
 
$296 
 
Non-ESC 
 
$504 
 
$431 
 
$443 
 
$445 
 
$465 
 
$465 
 
UCB-SC & 
Placental SC 
 
$43 
 
$35 
 
$28 
 
$32 
 
$32 
 
$32 
 
 
TOTAL 
FUNDING 
 
$868 
 
 
$811 
 
$917 
 
$939 
 
$983 
 
$983 
Note. SC = Stem Cell; hESC = human Embryonic Stem Cell; hiPSC = human induced Pluripotent Stem Cell; ESC = 
Embryonic Stem Cell; UCB = Umbilical Cord Blood 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 5 
National Institutes of Health Funding Rates for Human Stem Cell Research devoted to ASD 
  
Fiscal Year 
 
 
SC Type Researched 
 
 
2012 
 
 
2013 
 
 
2014 
 
 
2015 
 
     
 
hESC 
 
$562,927 
 
$594,332 
 
$53,282 
 
$56,042 
 
hiPSC 
 
$4,242,543 
 
$2,477,840 
 
$495,044 
 
$882,480 
 
Non-ESC 
 
$1,384,929 
 
$594,332 
 
$87,500 
 
$77,142 
 
UCB-SC & Placental SC 
(listed under Non-ESC) 
 
$0 
 
$0 
 
$0 
 
$0 
 
TOTAL FUNDING 
 
$6,190,399 
 
 
$3,666,504 
 
$635,826 
 
$1,015,664 
Note. SC = Stem Cell; hESC = human Embryonic Stem Cell; hiPSC = human induced Pluripotent Stem Cell; ESC = 
Embryonic Stem Cell; UCB = Umbilical Cord Blood.  There have been no estimated costs associated with Stem 
Cell research devoted to ASD for the years 2016 and 2017. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Table 6 
Institutional Funding Rates from the NIH for Human Stem Cell Research devoted to ASD 
 
Institution 
 
 
Total amount funded (2012-
2015) 
 
Number of grants received 
(2012-2015) 
 
Children’s Hospital of Orange County, CA 
 
$3,324,135 
 
6 
 
NIH, Md 
 
$3,305,437 
 
4 
 
Stanford University, CA 
 
$2,874,582 
 
14 
 
Hugo W. Moser Research Institute – Kennedy 
Krieger, Md 
 
$619,801 
 
1 
 
Scripts Research Institute, CA 
 
$460,152 
 
1 
 
Yale, CT 
 
$393,455 
 
1 
 
University of California - Davis 
 
$324,625 
 
3 
 
University of California – San Francisco 
 
$120,904 
 
1 
 
University of California – Los Angeles 
 
 
$85,318 
 
3 
 
TOTAL: 
 
$11,508,409 
 
34 
 
Note. NIH = National Institutes of Health 
  
 A multitude of clinically relevant research findings have been the result of such European 
or privately funded trials.   
An example of a key European trial was the 2014 open label, prospective, pilot-study 
conducted by EmCell (Ukraine) evaluating the efficacy of FSC transplantation in ASDs.  This 
was a multi-center (nine country) study with a primary endpoint objective to assess and establish 
the safety of FSC transplantation (FSCT) in children with autism.  The secondary endpoint 
objective was to evaluate the effectiveness of FSCT for reducing the core symptoms of ASDs 
(Bradstreet, Sych, et al, 2014).  The study design shows that 45 subjects were chosen who had a 
confirmed diagnosis of autism (DSM-IV-TR criteria).  The subject population consisted of 39 
males and 6 females ranging in age from 3 to 15 years old (mean = 6.94±0.89).  Subjects were 
monitored pre-implantation and then six and 12 months post-transplantations.  Transplantations 
consisted of two doses of intravenously and subcutaneously administered FSCs.  ASD tests were 
also performed on the subjects: The Autism Treatment Evaluation Checklist (ATEC) and the 
Aberrant Behavior Checklist (ABC).  In addition, laboratory examinations and clinical 
assessments of adverse effects (AEs) were performed in order to evaluate treatment safety.  The 
study findings resulted in no significant AEs observed in the treated subjects, including no 
transmitted infections or immunological complications.  Statistically significant differences 
(p<0.05) were noted on both the ATEC and ABC scores for the domains of speech, sociability, 
sensory, and overall health, as well as reductions in the total scores when compared to 
pretreatment values (Bradstreet, Sych, et al, 2014).  Although the results of this pilot-study are 
promising, further research is merited.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 While FSCs show promise in allogeneic use, NPSs need further research before proof of 
efficacy in clinical application. Moreover, Human Mesenchymal Stem Cells (hMSCs) and their 
subtypes have been the subject of the most recent research papers and numerous clinical trials 
associated with the use of stem cells in the treatment of autism spectrum disorders.  As of the 
date of this publication, a service of the NIH: clinicaltrials.gov, reported eight open clinical trials 
in the use of human Stem Cells (hSCs) for the treatment of ASDs (Table 2).  Four of said trials 
utilized bone marrow mononuclear cells as their intervention source, three trials utilized 
umbilical cord SCs, and one trial utilized adipose tissue derived cells.  Of these trials, all were 
privately funded and 7:8 were being conducted outside of the United States.   
As research continues to advance in efforts to uncover the most efficient and effective 
stem cell treatment for ASDs, current studies are revealing that a number of U.S. research 
institutions are establishing themselves as leaders in the field of stem cell therapy for ASDs.  The 
most prominent of these facilities is Duke University which has established the Duke Center for 
Autism and Brain Development.  Researchers at this facility, in conjunction with the Duke 
University Medical Center, are conducting a groundbreaking program of research to evaluate the 
efficacy of autologous and allogeneic cord blood for improving outcomes of children with 
autism spectrum disorders.   
Most recently (2017) Dr. Dawson and her colleagues at the Duke Stem Cell Transplant 
Laboratory published their findings related to their single-center phase I open label trial which 
demonstrated the safety and efficacy of autologous cord blood infusions to treat ASD.  In 
reviewing the study design and methods we find that twenty-five participants (21 males, 4 
females) were enrolled.  These participants ranged in age from 2 to 5 years, with a median age of 
4.62 years. The median nonverbal IQ equaled 65 (range 22-123). It was also reported that 72% 
of the participants had moderately severe or severe ASD symptoms. Inclusion measures for these 
participants was that they (a) must meet the clinical diagnostic criteria for an ASD diagnosis (per 
DSM-5 criteria), (b) must have a nonverbal intelligence quotient (IQ) of ≥ 35 on the Stanford-
Binet Intelligence Scales for Early Childhood, Fifth Edition or Mullen Scales of Early Learning, 
(c) have availability of a qualified autologous umbilical cord blood unit (viable CD34+), (d) the 
participant must be stable on their current medications for at least 2 months prior to the infusion, 
 (d) they must have the ability to travel to Duke University three times (baseline and 6 and 12 
months post-baseline), and (e) parents must be English speaking.  
Exclusion criteria included (a) a history of prior cell therapy, (b) use of intravenous 
immunoglobulin or other anti-inflammatory medications (with the exception of NSAIDs), (c) 
known genetic (e.g., fragile X) or other significant medical comorbidity, (d) obvious physical 
dysmorphology suggestive of a genetic syndrome, (e) an uncontrolled seizure disorder, (f) 
significantly impaired renal or liver function, and (g) clinically significant abnormalities in 
complete blood count (Dawson, Sun, et al, 2017).   
Procedurally, the subjects received a single intravenous infusion of autologous umbilical 
cord blood.   On the day of infusion, the cord blood was thawed and washed in dextran 40 + 5% 
albumin (DA) and placed in 1.25 ml/kg DA for administration (Rubinstein, Dobrila, et al; 1995). 
Thawed cord blood units were tested for enumeration of total nucleated cell count (TNCC), 
viable CD34+ cells, colony-forming units (CFUs), cell viability via trypan blue, and sterility 
cultures. The autologous umbilical cord blood infusion was performed following a sedated brain 
magnetic resonance imaging scan (MRI). IV access was obtained by a pediatric anesthesiologist. 
When the MRI was complete, children were admitted to the Duke Children's Health Center Day 
Hospital, an outpatient treatment center, for their infusion. After premedication with Benadryl 
(0.5 mg/kg IV), Solu-Medrol (0.5 mg/kg IV), and, if the child was awake and able to take oral 
medications, Tylenol (10 mg/kg PO), participants received either a portion of or their entire cord 
blood unit, adjusted to deliver 1–5 × 107 cells per kilogram, via peripheral IV infusion over 2 to 
30 minutes. Intravenous fluids were administered at 1.5 times maintenance for 30 minutes to 2 
hours after the cord blood infusion. (Dawson, Sun, et al, 2017). 
The primary endpoint of this trial was to evaluate the safety of autologous cord blood 
infusions in ASD patients.  Infusion reactions were monitored during time of procedure and 
additional AEs were identified through phone interviews with participants’ parent/guardian at 7-
10 days, 3 months, and 9 months after infusion.  Follow-ups were also made in person at 
baseline, and at 6- and 12-month clinic visits.  All reported AEs were graded as Mild (71 events) 
or Moderate (21 events). No serious AEs were reported.  13% of the AEs were considered 
related to the infusion, with the most common being allergic reaction, manifested by urticartia 
and/or cough occurring on the day of infusion (5 events in 4 participants; all Mild; 2 requiring an 
 additional dose of IV Benadryl). The most common unrelated AEs were agitation, skin changes, 
and typical childhood infections, reported between 2 days and 1 year post-infusion. There were 
no infusion-related infections or bloodstream or serious infections noted in any patient (Dawson, 
Sun, et al, 2017).  Dawson and her colleagues reported that the assessment of AEs over the 12-
months post-infusion indicated that cord blood infusions were safe and well tolerated. 
Secondary clinical assessments were also carried out to determine both feasibility of 
administration and utility as an endpoint for potential phase II and III clinical trials.  The 
assessments included the Vineland Adaptive Behavior Scales-II (VABS-II), Clinical Global 
Impression Scale (CGI), Pervasive Developmental Disorder Behavior Inventory (PDDBI), 
Expressive One-Word Picture Vocabulary Test-4 (EOWPVT-4), Behavior Assessment for 
Children-Social Skills subscale, Aberrant Behavior Checklist, Sensory Experiences 
Questionnaire, Repetitive Behavior Scale, Intelligence Scales (Mullen Scales of Early Learning 
or Stanford-Binet), Language Environment Analysis, Preschool Age Psychiatric Assessment, 
ATN GI Symptoms Inventory, and Parenting Stress Index. In addition, three objective 
biomarkers were collected: Eye Gaze Tracking of Social Stimuli (EGT), EEG, and brain MRI 
(Dawson, Sun, et al, 2017).  Dawson and her colleagues reported that significant improvements 
in behavior were found across a wide range of outcome measures including: improvements in 
parent-reported measures including the VABS-II Socialization, Communication, and Adaptive 
Behavior Scores and the PDDBI, clinician assessments including the CGI-S, CGI-I, and 
EOWPVT, and objective eye gaze tracking measurements. Most of the observed behavioral 
changes occurred during the first 6 months and were sustained between 6 and 12 months post-
infusion. A robust finding was that children's nonverbal IQ was correlated with change for the 
majority of outcomes measures, with higher nonverbal IQ being associated with greater 
improvements in behavior (Dawson, Sun, et al, 2017).   
The results of this study were robust enough that Dawson and her colleagues are now 
using these data to focus on a second study to determine the efficacy of umbilical cord blood 
infusions in children with ASD (DukeACT). This study tests the best available donor, which will 
include an allogeneic group in addition to autologous and placebo groups.   
  
 DukeACT is a Phase II, interventional, parallel group, single site, prospective, 
randomized, double-blind study of a single intravenous autologous or allogeneic [unrelated cord 
blood (CB)] infusion in children ages 2-7 years with Autism Spectrum Disorder (ASD). 
DukeACT anticipates their sample population to exceed 160 subjects to be followed for ≥12 
months.  Participants will be randomly assigned to Sequence A, consisting of a single infusion of 
CB cells at baseline followed 6 months later by a single infusion of placebo, or Sequence B, 
consisting of an infusion of placebo at baseline followed 6 months later by an infusion of CB 
cells. All participants will ultimately be treated with CB cells at some point during the study. 
Participants with an available qualified autologous CB unit will receive autologous cells, and 
those without a suitable autologous CB unit available will receive cells from a ≥4/6 HLA-
matched, ABO-matched allogeneic, unrelated donor CB unit from the Carolinas Cord 
Blood Bank. All infusions will be double-blinded. The primary outcomes will be assessed 6 
months after the initial infusion in the sequence. Additional testing for secondary exploratory 
analyses will be performed at 12 months. Duration of study participation will be 12 months from 
the time of baseline infusion. (ClinicalTrials.gov Identifier: NCT02847182). 
The significance of this study is multifold.   Duke researchers have addressed the fact that 
not all ASD patients and their families have access to autologous SC’s thus they have expanded 
their study to include allogeneic treatment options.  Secondly, the Duke Research team has 
created an exhaustive list of primary and secondary measures to be evaluated. And lastly, a 
suitable inclusion/exclusion criteria has been established. 
The primary endpoint of the DukeACT study is the change in social communication 
skills (a core symptom of autism) from baseline to six months after the initial study infusion, as 
measured by the Vineland Adaptive Behavior Scale (VABS)-II Survey Interview Form, 
Socializations Subscale Standard Score. The Control (placebo) and treated patients will be 
compared.  Whereas the secondary outcome measures to be evaluated include: Change in 
Vineland Socialization domain raw score and domain age equivalent (Time Frame: Baseline, 6 
months), change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) composite 
standard score (parent questionnaire) [Time Frame: Baseline, 6 months], Change in CGI-S and 
CGI-I (clinician assessment) [Time Frame: Baseline, 6 months ], Change in Expressive One-
Word Picture Vocabulary Test (clinician assessment) [ Time Frame: Baseline, 6 months ], 
 Change in Vineland Adaptive Behavior Communication subscale standard score, Daily Living 
subscale standard score, and Adaptive Behavior Composite [ Time Frame: Baseline, 6 months ], 
Change in individual subscales of the PDD-BI t scores [ Time Frame: Baseline, 6 months ], 
Incidence of infusion reactions [ Time Frame: 12 months ], Severity of infusion reactions [ Time 
Frame: 12 months ], Grade/severity will be assessed according to CTCAE v4.0 guidelines, 
Incidence of product-related infections [ Time Frame: 12 months ], Severity of product-related 
infections [ Time Frame: 12 months ], Grade/severity will be assessed according to CTCAE v4.0 
guidelines, Evidence of alloimmunization via anti-HLA and anti-RBC antibodies and 
nonspecific markers of systemic inflammation (ESR, CRP) [ Time Frame: 12 months ], 
Incidence of graft vs. host disease [ Time Frame: 12 months ], Severity of graft vs. host disease [ 
Time Frame: 12 months ], Grade/severity will be assessed according to CTCAE v4.0 guidelines, 
Incidence of unexpected adverse events, by relation to study product [ Time Frame: 12 months ], 
Severity of unexpected adverse events, by relation to study product [ Time Frame: 12 months ], 
and Grade/severity will be assessed according to CTCAE v4.0 guidelines.   
The inclusion/exclusion criteria indicate that both male and female subjects are accepted 
if their age is ≥ 2 years to ≤ 7 years (7 years, 364 days) at the time of visit 1 and if they have a 
confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using the DSM-5 Checklist. 
The subjects must also have Fragile X testing performed and show a negative result.  Subjects 
must also have available and qualified umbilical cord blood unit with a minimum banked total 
nucleated cell dose of ≥ 2.5 x 107 cells/kg that meets criteria outlined in their protocol which 
includes either autologous umbilical cord blood unit or ≥4/6 HLA-matched and ABO/Rh-
matched allogeneic unrelated umbilical cord blood unit from the Carolinas Cord Blood Bank. 
Subjects must also be stable on current psychiatric medication regimen (dose and dosing 
schedule) for at least 2 months prior to infusion of study product. They must have a normal 
absolute lymphocyte count (≥1500/uL). The participant and parent/guardian are English 
speaking and be able to travel to Duke University two times (baseline and 6 months post-
baseline), and parent/guardian must provide parental consent and be able to participate in interim 
surveys and interview.   
Subjects are also evaluated very stringently for exclusion criteria.  General exclusion 
criteria include: If a review of medical records indicates ASD diagnosis not likely, if there is a 
 known diagnosis of any of the following coexisting psychiatric conditions: depression, bipolar 
disorder, schizophrenia, obsessive compulsive disorder, Tourette syndrome.  If screening data 
suggests that participant would not be able to comply with the requirements of the study 
procedures, including study outcome measures, as assessed by the study team, they will be 
excluded.  If the family is unwilling or unable to commit to participation in all study-related 
assessments, including follow up for approximately 12 months, the subject will be excluded. 
And, if a sibling is enrolled in this study (DukeACT), a second is not allowed to enroll.   
In regards to genetic and infectious exclusion criteria, Duke states the following:  If 
records indicate that child has a known genetic syndrome such as (but not limited to) Fragile X 
syndrome, neurofibromatosis, Rett syndrome, tuberous sclerosis, PTEN mutation, cystic fibrosis, 
muscular dystrophy or known pathogenic copy number variation (CNV) associated with ASD 
(e.g., 16p11.2, 15q13.2, 2q13.3) they will be excluded.  If the subject has a known active central 
nervous system infection, has evidence of uncontrolled infection based on records or clinical 
assessment, or is HIV positive, the subject will be excluded.   
General medical exclusion criteria include: known metabolic disorder, known 
mitochondrial dysfunction, history of unstable epilepsy or uncontrolled seizure disorder, infantile 
spasms, Lennox Gastaut syndrome, Dravet syndrome, or other similar chronic seizure disorder, 
active malignancy or prior malignancy that was treated with chemotherapy, history of a primary 
immunodeficiency disorder, history of autoimmune cytopenias (i.e., ITP, AIHA), coexisting 
medical condition that would place the child at increased risk for complications of sedation or 
other study procedures, concurrent genetic or acquired disease or comorbidity(ies) that could 
require a future stem cell transplant, significant sensory (e.g., blindness, deafness, uncorrected 
hearing impairment) or motor (e.g., cerebral palsy) impairment, impaired renal or liver function 
as determined by serum creatinine >1.5mg/dL or total bilirubin >1.3mg/dL, except in patients 
with known Gilbert's disease, significant hematologic abnormalities defined as: Hemoglobin 
<10.0 g/dL, White blood count < 3,000 cells/mL, absolute lymphocyte count <1000/uL, Platelets 
<150 x 10e9/uL, or evidence of clinically relevant physical dysmorphology indicative of a 
genetic syndrome as assessed by the PIs or other investigators, including a medical geneticist or 
psychiatrists trained in identifying dysmorphic features associated with neurodevelopmental 
conditions (Kurtzberg, J., 2016). 
   The hope of such studies is to establish efficacy, safety, and tolerability parameters 
which will allow therapeutic access to all children affected with ASD rather than only to those 
who have access to banked autologous cord blood and, it is hopeful that research such as the 
DukeACT trial will continue to spawn additional studies to promote the advancement of stem 
cell treatments for ASD and other neurodevelopmental disorders. 
In an additional review written by Dr. Ichim and his colleagues (2007), they also studied 
the therapeutic benefits of cord blood CD34+ cells (autologous and allogeneic) however, they 
proposed the combined use of CD34+ cord blood cells with MSCs in the treatment of ASDs.  It 
is believed that the combining of MSCs with CD34+ induces synergistic effects in neurological 
diseases.   Ichim discusses the fact that MSCs have been proven to suppress pathological 
immune responses while also stimulating hematopoiesis which leads to the possibility that these 
cells may be useful for treatment of the defect in T cell numbers associated with autism (Ichim, 
Solano, et al; 2007). Several studies have also confirmed that systemic administration of cord 
blood cells is sufficient to induce neuroregeneration (Newman, Willing, et al, 2006; Chen, 
Chang, et al, 2006; Peterson, 2004). And, given the potency of cord blood CD34+ cells to induce 
angiogenesis in areas of cerebral hypoperfusion, it is proposed that this cell type would be 
particularly useful in the treatment of ASDs.   
Taking into account all sources of research data, to date, the most prolific and promising 
research published on the mesenchymal stem cell subtypes has been focused on the use of 
CD34+ umbilical cord cells however, we must recognize that further research is needed to 
understand these cells true mechanism of actions and their ability to act as ‘biophamacies’ 
capable of manufacturing a full array of cell-signaling chemistries.   
 
Discussion 
 As of 2017 there has been a significant break from U.S. medical dogma stating that adult 
stem cell therapies are unproven and that only embryonic stem cells should be considered for 
therapeutic study.  Duke University signaled its embrace of autologous stem cell therapy through 
their pivotal trials conducted at the Duke Stem Cell Transplant Laboratory, in conjunction with 
the Duke University Medical Center [Phase I & Phase II (DukeACT)].  
 Research and history have taught us lessons about stem cell research and its association 
to treating ASDs.  We have learned that ESC research has all but ceased not merely due to their 
overwhelming ethical and physiological burdens but more importantly, due to their numerous 
failed trials. We have come to understand that a reliable source of sufficient autologous NPCs 
needs to be identified therefore verifying that further research needs to be conducted before proof 
of efficacy can be demonstrated. We understand that the positive qualities and mechanism of 
action of FSCs may contribute to the success of allogeneic FSC transplants in ASD therapies. 
And, we have learned that most proliferative research has focused on MSCs and their subtypes 
due to their strong anti-inflammatory and immunosuppressive activities which render them very 
attractive for both autologous and allogeneic transplantations without requiring pharmacological 
immunosuppression.  In review, we are reminded that research confirms that these implanted 
stem cells (whether autologous or donor) are able to affect the recipient immune system through 
two proposed mechanisms: (1) cell-to-cell contact activation mechanism, through which 
transplanted stem cells switch proinflammatory macrophages to anti-inflammatory macrophages 
(Zheng, Ge, et al, 2013; Siniscalco, Giordano, et al, 2011), and (2) the paracrine-secretome 
activity (Zemel'ko, Kozhukharova, et al, 2013).   
Research also confirms that the biomedical facet of ASD treatment can be met with the 
burgeoning field of stem cell therapies. As of 2017, there are eight clinical trials registered with 
the United States National Institutes of Health (clinicaltrials.gov) all of which focused on a 
subtype of MSCs (Table 2). In addition to these registered trials, teaching institutions and private 
research facilities continue to offer ASD patients the opportunity to take part in their privately 
funded ASD treatment trials and treatments.   
The United States was the first to achieve the initial milestones in stem cell research and 
continues with cutting edge research protocols (e.g.: Duke trials) however, from a broad clinical 
scope we have learned that the United States is not currently recognized as offering the most 
advanced treatment options available for ASD treatments. The top ASD Stem Cell Therapy 
Treatment Centers can be found in numerous countries around the world. Pertinent to the stem 
cells discussed in this review, a selection of these ASD stem cell treatment centers are 
summarized in Tables 7-11. These centers offer promising ASD stem cell therapies which 
 include autologous and allogeneic options from a variety of stem cell types which were 
examined in this review.     
Table 7 depicts data on the Stem cell Institute which is located in Panama.  The Stem Cell 
Institute utilizes a five-day protocol of four intravenous infusions of human umbilical cord 
tissue-derived allogeneic mesenchymal stem cells.  This facility is one of the most tenured in 
offering ASD stem cell therapy, having performed over 10,000 procedures from 2006 through 
2017. 
 
Table 7 
Stem Cell Institute 
Treatment Center Stem Cell Institute 
 
Location(s) 
 
•Panama 
 
Source of Cells •Umbilical cord tissue-derived mesenchymal stem cells (allogeneic) 
•Umbilical cords are donated by mothers after normal, healthy births. Before they 
are approved for treatment all umbilical cord-derived stem cells are screened for 
viruses and bacteria to International Blood Bank Standards. In some cases, stem 
cells harvested from the patient’s own bone marrow are utilized (autologous). 
 
Number and Type of 
Treatments 
•Protocol: 
     -Treatment length (Monday – Friday): 5 Days 
     -Physical examination and blood testing: Monday 
     -4 intravenous infusions of human umbilical cord tissue-derived allogeneic 
mesenchymal stem cells: Tuesday – Friday 
•Administered intravenously by a licensed physician. 
 
Cost Dependent on type of treatment required 
 
Insurance Coverage None 
 
Effectiveness of Treatment •Performed over 10,000 procedures since 2006 but no efficacy rates provided 
 
Contact Information Web address: cellmedicine.com  
Address: BICSA FINANCIAL CENTER y  
Avenida, Calle Aquilino de la Guardia 
Panamá, Panama 
 
Aquilino de la Guardia Street 
BICSA Financial Center  
63rd Floor 
 
Toll Free (US Only): 1-800-980-STEM (7836) 
From Outside or Inside US Call: 1-954-358-3382 
Toll Free Fax (US Only): 1-866-755-3951 
From Outside US Fax: 1-775-887-1194 
 Beike Biotechnology – Stem Cell Treatment Center, with locations in China and Thailand, 
is yet another example of a facility which offers umbilical cord blood and umbilical cord tissue 
ASD treatments (Table 8).  Beike is a facility of importance due to its stringent treatment 
protocols which do not compromise on safety. These protocols have resulted in more than 22,500 
patients receiving ASD stem cell treatments with no serious adverse reactions being reported. 
 
Table 8 
Beike Biotechnology – Stem Cell Treatment 
Treatment Center Beike Biotechnology 
 
Location(s) 
 
•Shenzhen, China 
•Bangkok, Thailand 
 
Source of Cells Umbilical cord blood and umbilical cord tissue 
 
Number and Type of 
Treatments 
•Stem cell treatment protocols require a stay of 16 to 40 days depending on the 
treatment protocol prescribed for the patient specific condition. In addition to 
multiple stem cell administrations, a comprehensive therapy program is being 
provided on a daily basis throughout the entire treatment. 
•Made through intravenous or intrathecal injections 
 
Cost Case dependent  
 
Insurance Coverage None 
 
Effectiveness of Treatment •Beike treatment protocols do not compromise on safety and adult stem cells 
have been used effectively for more than 22,500 patients with no serious 
adverse reaction reported. 
•ASD patients have experienced Improved social interaction better 
communication, improved speech, improved learning ability, decreased 
repetitive behavior, better mental development, improved bowel movement, and 
increased muscle tone 
 
Contact Information Web address:  beikebiotech.com, stemcelltreatmentnow.com 
Tel: +86 755 8630 9200 
Address: 16F Beike Building, 18 Keyuan Rd., 
South Area, Hi-Tech Industrial Park, 
Nanshan, Shenzhen, China 518057 
Note. ASD = Adult Stem Cell. 
 
 
 
 The Regeneration Center of Thailand (Table 9) offers a 10 to 17 day protocol of enriched 
MSC injections for the treatment of ASD.  This facility boasts an overall efficacy rate of 85% in 
over 2,500 patients treated (as of the year 2017).   
 
Table 9 
Regeneration center of Thailand 
Treatment Center Regeneration Center of Thailand 
 
Location(s) 
 
Bangkok, Thailand 
 
Source of Cells 
 
•Hematopoietic Mesenchymal Enriched Stem cells 
•The age and lack of physical development of a child may prohibit them from 
donating stem cells from adipose (fat) tissue or bone marrow or dental pulp 
derived stem cells. If the child is not a candidate for Autologous therapy or 
has severe conditions then Allogeneic HLA matched Mesenchymal stem 
cells from cord blood, amniotic membrane or placenta derived cells will be 
used after HLA matching is complete. 
 
  •2 to 6 Enriched Mesenchymal Stem Cell Injections per treatment stage.  
•10 to 17 days  
•Multiple stages may be required for severe cases 
•Depending on the patients requirements the treatment injections will be 
made via a Guided CT Scanner (when necessary) or through a non-invasive 
and painless Intravenous Drip without anesthesia. Direct injections or 
Intrathecal injections may be required in some cases. 
 
Cost Case dependent 
 
Insurance Coverage None 
 
Effectiveness of Treatment Overall efficacy of treatments is rated at 85% in approximately 2,500 patients 
treated 
 
Contact Information Web address: stemcellthailand 
Address: 10110 Bangkok Klongton-Nue, 808/8 Thararom 2, Sukhumvit 55 
FL 2, Thailand 
Tel: (+66) 808 069 391  
Email: info@stemcellthailand.org 
Note. HLA = Human Leukocyte Antigen; CT = Computed Tomography. 
 
 
 
 
 EmCell Treatment Center (Table 10) is a facility that is on the forefront of ASD-SC treatments 
and research, having conducted clinical trials evaluating the efficacy of FSC transplants in 
ASDs.  EmCell has treated more than 300 autistic children to date (2017) with an overall success 
rate of 81%.  Their data also reports that 91% of treatments resulted in increased attention, 
concentration, self-care, verbal skills, resolution of bowel problems, and overall functional 
independence.   
 
Table 10  
EmCell Treatment Center 
Treatment Center EmCell (Cell Therapy Center) 
 
Location(s) 
 
Ukraine 
 
Source of Cells •7–12 week old fetal stem cells harvested from legally aborted embryos and 
subjected to multiple safety testing. These cells preserve their pluripotent 
properties 
 (ability to differentiate into cells of different germ layers: mesenchymal, ecto- 
and endodermal) and are the most effective in different diseases and conditions. 
 
Number and Type of 
Treatments  
•Average duration of FSC treatment course varies from 2 to 5 days and depends 
on the diagnosis, history of illness, complications or concomitant diseases. In 
order to inform the patient about the time needed for treatment, we require 
providing us with basic medical data. 
•Treatment is administered intravenously into the arm vein and/or subcutaneous 
injections are made in the frontal abdominal wall. 
 
Cost •Price of the treatment is defined by many factors such as: diagnosis, patient’s 
condition, number of types of cells, which are used during the treatment.  
•The price of the treatment may vary from $68,000 to $80,000 USD 
 
Insurance Coverage None 
 
Effectiveness of Treatment •Treated >300 autistic children with success rate of 81% 
•91% of treatments resulted in increased attention, concentration, self-care, 
verbal skills, resolution of bowel problems, and overall functional independence. 
 
Contact Information Web address: emcell.com 
Tel.: +38 044 223 28 95 
Fax: +38 044 468 80 29 
Address: 37 A Syretska street, Kyiv 04073, UKRAINE 
Note. FSC = Fetal Stem Cell; USD = United States Dollars.  
 
A treatment center that incorporates gene therapies with their stem cell treatments for 
their ASD protocols is: Stem Cell Genetic Med, located in Wellington Florida (Table 11).  Stem 
 Cell Genetic Med offers a unique protocol for their ASD patients.  Potential patients are 
evaluated by checking for abnormal gene mutations or mitochondrial abnormalities.  If an 
individual is found to be a candidate for their treatment, a one day protocol is established.  The 
concept of their protocol is to rewire the brain allowing nerve cells to communicate through their 
axons not only locally but to distant areas of the brain. 
Table 11 
Stem Cell Genetic Med Treatment Center 
Treatment Center Stem Cell Genetic Med 
 
Location(s) 
 
Wellington, Florida 
 
Source of Cells Autologous SC’s harvested from bone marrow or adipose tissue 
 
Number and Type of 
Treatments 
•One day protocol 
•Consists of a four step process: (1) harvesting SC’s from patient, (2) separation 
of SC’s, (3) activation of SC’s – enriched with patients own blood plasma, (4) 
treatment via intravenous drip method. 
•Combination protocol: Treatment consists of a combination of stem cell and 
gene therapies. Patients are evaluated by checking for abnormal gene     
mutations or mitochondrial abnormalities.  
  (1)When a gene mutation is discovered it is knocked out by a specific shRNA 
agent 
  (2)This is followed by inserting the normal gene into the DNA of neural brain 
stem cells using an attenuated viral vector. 
  (3)The next step is the administration of neural brain stem cells with the normal 
gene into the brain and central nervous system along with BDNF, NGF, NT, 
GDNF, CDGF, and VEGF by lumbar spinal tap.  
  (4)Patients post treatment are given neuro brain stimulation externally with a 
device applied to the forehead and scalp twenty minutes a day. 
  (5) Hyperbaric oxygen treatments 
The general concept is to rewire the brain allowing nerve cells to communicate 
through their axons not only locally but to distant areas of the brain. 
 
Cost Not indicated 
 
Insurance Coverage None 
 
Effectiveness of Treatment Not indicated 
 
Contact Information Web address:  stemcellgeneticmed.com 
Address: 10111 Forest Hills Blvd  
Suite 255 
Wellington, FL 33414 
Main Tel: (561) 557-3358 
Email: bfeinermanstemcells@gmail.com 
Note. SC = Stem Cell; BDNF = Brain-Derived Neurotrophic Factor; NGF = Nerve Growth Factor; NT = 
Neurotrophins; GDNF = Glial Derived Neurotrophic Factor; CDGF = ciliary derived growth factor; VEGF = 
vascular endothelial growth factor 
  
 As of 2017, these data associated with research and outcomes shows promise for the 
future of stem cell treatments associated with autism spectrum disorders. 
 
Conclusion 
This review advances the knowledge in the field of stem cell therapies for autism 
spectrum disorders first by providing an up to date educational foundation of the stem cells used 
in the treatment of ASDs, the most current treatment and research options, as well as current 
outcomes and funding data.  Secondly, this review was meant to promote a contemplative 
framework for current and future stem cell scientists in the field of ASD research which might 
stimulate future preclinical and clinical studies. This review also provides a comparison of 
current procedures and outcomes achievable internationally to that of the United States. And, 
lastly, the treatment that an ASD patient and their family might choose to receive simply due to 
reading this review, or the totality and magnitude of potential novel research conducted simply 
through reading this review, could be life changing and groundbreaking.   
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